(Reuters) -GSK raised its 2025 sales and earnings expectations on Wednesday after third-quarter results beat forecasts, helped by double-digit growth for its HIV and cancer drugs.

This is CEO Emma Walmsley’s last quarterly update before Luke Miels takes over in early 2026 to steer the drugmaker through U.S. trade tariffs, pricing battles, and a push for new medicines to offset revenue declines as some top-selling medicines go off patent.

Investors are counting on Miels to lay down the path for GSK to reach its annual revenue target of more than 40 billion pounds ($53.68 billion) by 2031. Analysts currently estimate sales to be at about 34 billion pounds.

The drugmaker expects annual revenue to increase in the range of 6%-7%, and core earnings per share to increase by 10%-12%. GSK said t

See Full Page